» Articles » PMID: 24012083

Psychopharmacologic Treatment of Psychosis in Children and Adolescents: Efficacy and Management

Overview
Date 2013 Sep 10
PMID 24012083
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The efficacy of antipsychotic use in children and adolescents with psychosis has been shown in an increasing number of randomized controlled trials. Chronic use of second-generation and third-generation antipsychotics has the potential for significant side effects, especially metabolic syndrome. A review of the literature on side effect profiles of antipsychotic medications used in children and adolescents is provided to help clinicians develop treatment plans for their patients. Clozapine has the best efficacy of all antipsychotic medications in adults as well as children and adolescents who are treatment resistant. Guidance is provided for the management of clozapine side effects.

Citing Articles

Treatment Analysis of Very Early and Early Onset Psychosis in the Youth Inpatient Setting.

Summerson A, Kalosieh J, Kompella S, Villalba C, Kodali Y HCA Healthc J Med. 2025; 5(6):661-670.

PMID: 39790696 PMC: 11708942. DOI: 10.36518/2689-0216.1637.


Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review.

Sepulveda-Lizcano L, Arenas-Villamizar V, Jaimes-Duarte E, Garcia-Pacheco H, Paredes C, Bermudez V Eur J Investig Health Psychol Educ. 2023; 13(8):1505-1520.

PMID: 37623307 PMC: 10453914. DOI: 10.3390/ejihpe13080110.


Interest of Fluvoxamine as an Add-On to Clozapine in Children With Severe Psychiatric Disorder According to CYP Polymorphisms: Experience From a Case Series.

Berel C, Mosse U, Wils J, Cousin L, Imbert L, Gerardin P Front Psychiatry. 2021; 12:669446.

PMID: 34234701 PMC: 8255476. DOI: 10.3389/fpsyt.2021.669446.


Bibliography: Schizophrenia: Advances in Understanding and Treatment.

Focus (Am Psychiatr Publ). 2020; 14(3):361-362.

PMID: 31997956 PMC: 6526800. DOI: 10.1176/appi.focus.140304.


A Review of Childhood-Onset Schizophrenia.

Kendhari J, Shankar R, Young-Walker L Focus (Am Psychiatr Publ). 2020; 14(3):328-332.

PMID: 31975813 PMC: 6526799. DOI: 10.1176/appi.focus.20160007.